Company intelligence / Profile preview
Gilead Sciences
- Ownership
- Public · GILD
- Employees
- ~17600
- Development stage
- Commercial
Overview
Gilead has a broad portfolio of commercialized products in virology—especially HIV/AIDS and viral hepatitis—and oncology. Its HIV regimens are global standards of care. Hepatitis C drugs like Sovaldi and Harvoni have achieved high cure rates. Remdesivir was the first antiviral approved for COVID‑19 treatment. In oncology/cell therapy through Kite Pharma’s Yescarta and Tecartus CAR-Ts for lymphomas/leukemias are FDA-approved.
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- Small moleculesmonoclonal antibodies (mAbs)cell therapies (CAR-T)antivirals
- Industry
- Pharma
Drug pipeline
255 assets254 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $207B
- Total revenue
- $29.4B
- Enterprise value
- $226.8B
Beyond the preview
Go deeper on Gilead Sciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gilead Sciences.